<DOC>
	<DOCNO>NCT02388620</DOCNO>
	<brief_summary>The purpose study evaluate pharmacokinetics ( PK ) , safety tolerability single oral dose LEE011 subject vary degree impair hepatic function ( base Child-Pugh classification ) compare demographically-matched control subject normal hepatic function .</brief_summary>
	<brief_title>Evaluation Hepatic Function Impairment Pharmacokinetics LEE011</brief_title>
	<detailed_description />
	<criteria>All Subjects : Male female ( sterile postmenopausal ) subject 1875 ( inclusive ) year age healthy determine absence clinically significant deviation normal medical history , physical examination , vital sign , electrocardiogram , clinical laboratory determination . Subjects must BMI 18 kg/m2 36 kg/m2 weight least 50 kg 120 kg . Other hepatic impairment , subject must good health determine past medical history , physical examination , vital sign , electrocardiogram , ( except additional inclusion criterion describe ) . Subjects ChildPugh A , B C cohort : Additional inclusion criterion ChildPugh Clinical Assessment Score consistent degree hepatic impairment No change hepatic status least one month prior dose ( i.e . worsen ChildPugh score ) . All Subjects : Subject receive liver transplant time past immunosuppressant therapy . History presence impair cardiac function Any surgical medical condition may significantly alter absorption , distribution , metabolism excretion drug Administration CYP3A4/5 inhibitor inducer CYP3A4 substrates narrow therapeutic window Administration medication prolong QT interval History immunodeficiency disease , include HIV , confirm ( HIV1 , HIV2 ) test . Participation another clinical trial within 4 week prior study drug administration . Subjects normal hepatic function : Additional exclusion criterion A positive Hepatitis B surface antigen ( HBsAg ) Hepatitis C test result . Subjects ChildPugh A , B C cohort : Additional exclusion criterion Clinical evidence severe ascites ( e.g . require regular tapping ) . Bilirubin &gt; 6 mg/dL</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>